CJC1295 no DAC – 2mg & 5mg
CJC-1295 (No DAC)
Primary Application: Pulsatile Growth Hormone Release and Restorative Sleep Research
Fundamental Information
-
Alternative Name: Modified GRF (1-29) or Mod-GRF
-
Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
-
Molecular Formula: C152H252N44O42
-
Molecular Weight: 3367.9 Daltons
-
Half-Life: Approximately 30 minutes
Detailed Overview
CJC-1295 (No DAC), technically referred to as Modified GRF (1-29), is a refined version of the 29-amino acid chain that makes up the active part of Growth Hormone-Releasing Hormone. While the original version (Sermorelin) is destroyed by the body in less than 10 minutes, scientists modified this peptide at four specific points (positions 2, 8, 15, and 27) to make it significantly more stable and resistant to metabolic breakdown. This version lacks the “Drug Affinity Complex,” meaning it does not bind to blood proteins and is cleared from the system quickly.
The short lifespan of this peptide is its primary research advantage. Because it is cleared quickly, it triggers a sharp, rapid pulse of growth hormone shortly after administration before allowing levels to return to baseline. This “pulsatile” pattern closely mimics the body’s natural hormonal rhythm, particularly the large spikes of growth hormone that occur during deep sleep. Research often focuses on this peptide for improving body composition, enhancing muscle recovery, and deepening slow-wave sleep. By maintaining the body’s natural “peaks and valleys” of hormone release, the No DAC version is studied for its ability to provide therapeutic benefits while minimizing the risk of pituitary desensitization.
Scientific References
-
Jette L, et al. “Human growth hormone-releasing factor (hGRF) 1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.” Endocrinology. 2005.
-
Frohman LA, et al. “Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo.” Journal of Clinical Investigation. 1986.
-
Teichman SL, et al. “Pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.” J Clin Endocrinol Metab. 2006.
